Author
Andrew H. Ko
Also Known As
A H Ko, A. H. Ko, A. Ko, A.H. Ko, ANDREW H. KO, Andrew H Ko, Andrew H. Ko, Andrew Ko, Andrew T Ko, Andrew T. Ko
298
Publications
16.9K
Citations
49
H-Index
89
Concepts
All Affiliations
| # | Concept | H-Index | Publications | Citations |
|---|---|---|---|---|
1 | Medicine | 28 | 48 | 6.4K |
2 | Health Sciences | 10 | 11 | 1.4K |
3 | Cell Biology | 4 | 4 | 319 |
4 | Public Health | 3 | 3 | 175 |
5 | Cellular Therapies | 1 | 1 | 137 |
Andrew H. Ko
×
91
Publications
13.6K
Citations
45
H-Index
| Year | Citations | |
|---|---|---|
2011 | 1.9K | |
2021 | 1.6K | |
2021 | 1.2K | |
2020 | 1.1K | |
2017 | 1K | |
2014 | 463 | |
2016 | 371 | |
2019 | 365 | |
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial Lacey Padrón, Deena M. Maurer, Mark H. O’Hara, Randomized Phase 2Pancreatic CancerGastrointestinal OncologyMedicineImmunologic Analyses | 2022 | 316 |
2012 | 304 |
Page 1
Page 1